The European Commission has granted conditional marketing authorization for Minjuvi (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
As a science journalist living in the epicenter of the measles outbreak, I did what any reporter would do when I was assigned this story—I texted my medical friends.
